Launch of Phase I clinical trials of an Novartis Alzheimer’s Vaccine

Published 25 June 2007

Initial studies with the Alzheimer vaccine were seen as the most exciting treatment development ever investigated for the treatment of dementia.

'However, problems arose because of the potential for these treatments to cause serious side effects.
This new vaccine is potentially promising as scientists hope they have found a way to limit adverse reactions in people.
A successful vaccine for Alzheimer's disease would be a groundbreaking treatment advance for the 25 million people with Alzheimer's disease worldwide. More funding and research in to this important area is urgently needed.'